ASBM Executive Director Michael Reilly was quoted in the FDA Week story Stakeholders Draw Biosimilar Naming Insight From Biologic Approval.
Read the article.
Media Room
ASBM Quoted in FDA Week Story on Naming
Friday, September 7th, 2012
Friday, September 7th, 2012
ASBM Executive Director Michael Reilly was quoted in the FDA Week story Stakeholders Draw Biosimilar Naming Insight From Biologic Approval.
Read the article.